Semprus socks away $18M in Series B funds
Cambridge-based biomedical company focused on antibacterial coatings Semprus BioSciences Inc. has closed on an $18 million Series B financing round, led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners.
According to Semprus officials, 5AM Ventures and Pangaea Ventures, both of whom invested in the company’s Series A financing, participated in the Series B round. Added to a $10.5 million Series A round that closed in 2008, Semprus has now brought in $28.5 million in VC funds. John Sullivan, principal at Foundation Medical Partners and Simeon George, partner at SR One, will join the Semprus board of directors.